Alleviare Life Sciences Private Limited

Alleviare Life Sciences Private Limited is a privately held pharmaceutical company established on December 10, 2013, in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U74999DL2013PTC261897 and is classified as a non-government company limited by shares. Its authorized capital is ₹1.0 million, with a paid-up capital of ₹0.43 million.

The company's registered office is located at S-9, Mezzanine Floor, Uphaar Cinema Complex, Green Park Extension, New Delhi, Delhi, 110016, India. Alleviare Life Sciences specializes in the global export of specialty drugs, including vaccines and cold chain pharmaceutical products, as well as general pharmaceutical products. Additionally, the company provides consulting services to Indian patients for medicines that are not available or registered in India, assisting with documentation, logistics, and procurement from international authorized suppliers.

Specific details regarding Alleviare Life Sciences Private Limited's manufacturing facilities are not publicly disclosed. The company primarily focuses on the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, rather than manufacturing raw active pharmaceutical ingredients (APIs) or bulk drugs. This strategic approach suggests that Alleviare Life Sciences may partner with established manufacturers to produce its product offerings.

As of November 15, 2023, the directors of Alleviare Life Sciences Private Limited are Vaibhav Bansal and Puneet Poddar. The company's leadership team comprises professionals with extensive experience in the pharmaceutical industry, enabling Alleviare Life Sciences to supply and deliver a wide range of products within short notice.

Alleviare Life Sciences Private Limited's export activities are primarily focused on the Indian market, with limited publicly available information regarding its presence in other regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan. The company's export value of $77,000 USD across 18 shipments, with a portfolio concentration of 100% in the Advanced Oncology therapeutic category, indicates a niche market focus. The top three exported products—Daratumumab, Pembrolizumab, and Lenvatinib—are all oncology treatments, suggesting that the company may be targeting markets with a high demand for cancer therapies.

Alleviare Life Sciences Private Limited's export data does not provide specific insights into its penetration in emerging markets such as Africa, Latin America, and Southeast Asia. The company's focus on specialty drugs, including oncology treatments, may position it to explore opportunities in regions with growing healthcare needs and increasing demand for advanced medical therapies. However, without explicit information on regulatory approvals or market access in these regions, a comprehensive assessment is challenging.

Alleviare Life Sciences Private Limited's export strategy appears to be concentrated in the Advanced Oncology therapeutic category, with a portfolio concentration of 100% in this area. This focus suggests a strategic direction aimed at addressing the global demand for oncology treatments. The company's export value of $77,000 USD across 18 shipments indicates a selective approach to market entry, potentially mitigating risks associated with overextension. However, the lack of diversification in therapeutic areas may expose the company to market fluctuations and regulatory challenges specific to oncology products.

Publicly available information does not disclose Alleviare Life Sciences Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. The company's export data indicates a focus on finished pharmaceutical formulations, including oncology treatments, but without explicit details on FDA approvals or compliance, a thorough assessment of its standing with the U.S. Food and Drug Administration is not feasible.

There is no publicly available information confirming whether Alleviare Life Sciences Private Limited holds World Health Organization (WHO) prequalification or European Union Good Manufacturing Practice (EU GMP) certificates. The company's export data suggests a focus on finished pharmaceutical formulations, but without explicit details on WHO or EU GMP certifications, an assessment of its compliance with these international standards cannot be made.

Alleviare Life Sciences Private Limited is registered with the Ministry of Corporate Affairs under the Corporate Identification Number (CIN) U74999DL2013PTC261897. The company's registered office is located at S-9, Mezzanine Floor, Uphaar Cinema Complex, Green Park Extension, New Delhi, Delhi, 110016, India. Specific details regarding the company's manufacturing licenses, state drug controller approvals, or export No Objection Certificates (NOCs) from the Central Drugs Standard Control Organisation (CDSCO) are not publicly disclosed.

There is no publicly available information indicating that Alleviare Life Sciences Private Limited has received any Form 483 observations, warning letters, or import alerts from regulatory authorities. The company's export data and available corporate records do not provide evidence of recent regulatory actions or compliance issues.

Alleviare Life Sciences Private Limited operates in the competitive pharmaceutical export market, focusing on specialty drugs, particularly in the oncology therapeutic area. While specific competitors are not identified in the available data, the company's niche focus on oncology treatments positions it within a specialized segment of the market. The export value of $77,000 USD across 18 shipments suggests a selective approach to market entry, potentially targeting regions with high demand for oncology therapies. However, without explicit information on market share or direct competitors, a detailed competitive analysis is not feasible.

Alleviare Life Sciences Private Limited's key differentiators include its specialization in the export of specialty drugs, particularly oncology treatments, and its consulting services for Indian patients seeking access to medicines not available or registered in India. The company's focus on finished pharmaceutical formulations, including vaccines and cold chain products, indicates a commitment to providing comprehensive solutions in the pharmaceutical export sector. Additionally, the leadership team's extensive experience in the pharmaceutical industry enables the company to supply and deliver a wide range of products within short notice.

Alleviare Life Sciences Private Limited's current strategic direction appears to be focused on the export of specialty drugs, with a particular emphasis on oncology treatments. The company's portfolio concentration of 100% in the Advanced Oncology therapeutic category suggests a targeted approach to addressing global demand for cancer therapies. The export value of $77,000 USD across 18 shipments indicates a selective market entry strategy, potentially mitigating risks associated with overextension. However, the lack of diversification in therapeutic areas may expose the company to market fluctuations and regulatory challenges specific to oncology products. Without explicit information on future plans, a comprehensive assessment of the company's strategic outlook is not feasible.

Alleviare Life Sciences Private Limited's export data indicates a focus on finished pharmaceutical formulations, including oncology treatments. The company's export value of $77,000 USD across 18 shipments suggests a selective approach to market entry, potentially mitigating risks associated with overextension. However, without explicit information on supplier relationships, manufacturing capabilities, or compliance with international standards, a thorough assessment of the company's reliability as a supplier is not feasible.

Importers considering Alleviare Life Sciences Private Limited as a supplier should verify the following certifications:

• FDA Facility Registration: Confirm that the company's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA). This can be verified through the FDA's official website or by contacting the company directly.

• WHO-GMP Certification: Ensure that the company holds World Health Organization (WHO) Good Manufacturing Practice (GMP) certification. This can be verified by checking the WHO's official website or by requesting certification details from the company.

• EU GMP Certification: Verify that the company complies with European Union Good Manufacturing Practice standards. This can be confirmed by consulting the European Medicines Agency (EMA) or by obtaining certification information from the company.

• ISO Certification: Check for International Organization for Standardization (ISO) certifications related to quality management systems. These can be verified by reviewing the company's official documents or by contacting the company directly.

Importers should undertake the following steps to ensure a comprehensive evaluation of Alleviare Life Sciences Private Limited:

• Verify Regulatory Compliance: Confirm that the company holds necessary certifications such as FDA registration, WHO-GMP, EU GMP, and ISO certifications.

• Assess Financial Stability: Review the company's financial statements to evaluate its financial health and stability.

• Evaluate Product Quality: Request samples and conduct quality assessments to ensure that products meet required standards.

• Review Supply Chain Practices: Examine the company's supply chain processes to ensure reliability and